What is the actual first-pass clearance rate for cyber-relevant 510(k)s?

Hard public number. Industry estimates put first-cycle clean cybersecurity at roughly 30-40% across all submitters. Specialist MedTech cyber teams report 80%+ first-cycle clean when the eight artifacts are built to the 2026 guidance. The delta is not luck.

Do all 510(k) submissions need this full package?

Any device meeting the Section 524B definition of cyber device does. That is essentially every device with software that includes the ability to connect to the internet or networked device, or that contains software validated, installed, or authorized by the manufacturer that the manufacturer intentionally and technologically connects to a digital system. In 2026 that is most 510(k)s.

How does this differ from De Novo and PMA?

510(k) leans heavily on the predicate-comparison narrative because there is a predicate. De Novo replaces the predicate-comparison with a security-architecture-justification (no predicate exists). PMA requires the deepest documentation but the artifact list is similar.

What if our predicate is older and has no cybersecurity evidence?

Common situation. The predicate-comparison narrative becomes more important, not less - you describe the new cyber surface introduced by your device against the predicate baseline and show the cyber risks and controls for that delta. Reviewers do not expect you to retroactively cyber-document the predicate.

Can we file a 510(k) without a Letter of Attestation if our pen tester does not provide one?

You can file, but expect a deficiency citing the missing attestation. Easier to require it from your pen test vendor up front than to litigate it after submission.

Is third-party pen testing required, or can we self-test?

The guidance does not require third-party testing, but in practice independent testing is what reviewers find credible. Self-tested submissions consistently draw deeper scrutiny on methodology and scope.

What happens if we file before our SBOM is complete?

Likely AI letter (Additional Information) request specifically calling for the SBOM. Easier to delay the submission a week than to consume 60+ days of the deficiency clock on a missing artifact.

Does this package satisfy EU MDR cybersecurity expectations too?

Mostly. EU MDR Annex I cybersecurity requirements overlap heavily with FDA §524B; IEC 81001-5-1 and IEC 62443-4-1 add lifecycle process evidence requirements that you can document in a process-evidence appendix. One artifact set, multi-region acceptance.

How long does it take to build the eight artifacts from scratch?

8-14 weeks for a connected Class II device with engaged engineering. Threat modeling and pen testing can run in parallel after the architecture intake.

What is the single highest-value thing to get right?

The traceability matrix. If a reviewer can follow threat → control → verification → residual risk → ISO 14971 harm without leaving the document, most other deficiencies do not get raised because the answer is visible.

How to Pass FDA 510(k) Cybersecurity on the First Submission

Direct Answer

How do you pass FDA 510(k) cybersecurity review on the first submission?

Clearing 510(k) cybersecurity on the first submission generally requires eight artifacts built to the February 2026 final guidance: a security risk assessment, a traceable threat model, an SBOM, a penetration test report, architecture views, cybersecurity labeling, a postmarket plan, and a predicate-comparison narrative addressing every new cyber surface. Running a 30-day readiness check against these artifacts before eSTAR upload catches most issues that otherwise trigger an AI letter.

Talk to a MedTech cybersecurity expert

The eight artifacts a clean 510(k) cybersecurity package contains

Security risk assessment aligned with AAMI TIR57 / SW96.
Threat model with four architecture views and traceability matrix.
SBOM in CycloneDX or SPDX with vulnerability disclosure paths.
Penetration test report with full attack surface coverage and Letter of Attestation.
Architecture views (global, multi-patient harm, updateability, security use-case).
Cybersecurity labeling and user-facing security information.
Postmarket cybersecurity management plan.
Predicate-comparison cybersecurity narrative.

Predicate divergence: the silent killer

The most common 510(k) cybersecurity deficiency is the same every cycle: the device has connectivity or features the predicate did not, and the submission does not address the resulting cybersecurity delta. Reviewers look for an explicit predicate-comparison cybersecurity narrative that lists every interface and data flow added beyond the predicate, identifies the new threats those create, and shows the controls that mitigate them. Without this narrative, even a strong threat model and pen test will draw a deficiency because the reviewer cannot tell what is 'new' from what was inherited.

The 30-day pre-submission readiness check

A focused review against the eight artifacts catches the 80% of issues that cause first-cycle deficiencies. Run it 30 days before planned eSTAR upload.

Day 1-5: Artifact completeness

All eight artifacts present and version-controlled.
Each artifact has clear authorship, date, and version.
Cross-references between artifacts resolve (no broken links).

Day 6-15: Content depth

Threat model: four architecture views present, trust boundaries consistent across views, STRIDE per element.
Pen test: Letter of Attestation present, scope covers full attack surface, retest evidence for high/critical.
SBOM: machine-readable, transitive deps, VEX or equivalent triage statement.

Day 16-25: Traceability

Threat → control → verification → ISO 14971 harm chain unbroken.
Predicate-comparison narrative present and complete.
Postmarket plan describes monitoring cadence, vulnerability triage SLA, and patch deployment.

Day 26-30: Reviewer-eye read-through

A senior MedTech regulatory reader who did not write the package reads it cold. If they cannot answer "what does this device do, what are the cyber threats, and how are they controlled" in 15 minutes from the package alone, the package is not ready.

Common rejection patterns we still see in 2026

IT-style threat model presented as medical device threat model - no patient-safety mapping.
Pen test scoped to web app only because the device is "just a sensor with an app."
SBOM present but cloud backend excluded.
Postmarket plan describes monitoring intent without cadence, SLAs, or named owners.
AI/ML feature added but no AI-specific cybersecurity content - no MITRE ATLAS mapping, no model-supply-chain review.
Cybersecurity labeling missing entirely or buried in a single sentence in the IFU.

If a deficiency does come

You have 180 days. Fast response matters more than long response. See our FDA cybersecurity deficiency response timeline and sequencing for the structure that gets through second-cycle review without a third.

Frequently asked questions

What the first submission usually gets wrong

Across first-time 510(k) cybersecurity packages, the failures cluster into three shapes, and none of them are about missing documents.

The package is complete but not connected. Every artifact exists, and none of them reference each other. The threat model enumerates 60 threats, the risk assessment scores 44 risks, the control list names 31 controls, and no identifier appears in more than one document. A reviewer cannot verify that the mitigation for threat 17 was tested, so the whole set is treated as unverified.

Testing was scoped to the app, not the device. The pen test covers the mobile application and the cloud API, while the firmware, the debug port, the pairing sequence, and the update mechanism are untested. That gap is visible from the report's scope section in about ten seconds.

The postmarket plan describes an intention. It says vulnerabilities will be triaged promptly and patches released as needed, with no defined intake, no owner, no timeline, and no update mechanism described. Section 524B(b)(1) requires the plan to be real at clearance, not after.

A pre-flight test you can run in an afternoon

Hand the package to someone who did not write it, with one instruction: pick three threats at random from the threat model and trace each one to a scored risk, a named control, an implementation location, and a test result. Then pick two findings from the pen test report and trace each back to a threat and to a remediation record.

Five traces. If any one of them breaks, the reviewer's version of the same exercise breaks too, and that produces the traceability deficiency that costs a review cycle. This is a cheaper failure to find internally than to find in a letter.

The timing mistake that causes most first-submission delays

Teams schedule penetration testing to finish the week the submission goes out. Two things then go wrong. There is no time to remediate what the test finds, so the report ships with open findings and no fix evidence. And because the test ran against a build that was still changing, the report describes a version that no longer matches the submitted firmware.

Book independent testing to complete six to eight weeks before your target filing date. That leaves room for remediation, a focused retest of the fixed items, and a final report that matches the shipping build. Every other artifact can be finished in the last month; this one cannot.

Where to go next

Passing cybersecurity on the first 510(k) submission is mostly a calendar exercise. The technical work is well understood. What separates a clean clearance from a deficiency letter is whether the work happened in an order that let findings change something.

Set your dates backwards from the filing target. Nine months out, the architecture and data flow documentation should be stable enough to threat model against. Seven months out, the threat model should be complete, reviewed, and already reflected in design decisions. Five months out, penetration testing starts, scoped from that threat model. Three months out, findings are remediated and retested, and the report is final. The last two months are assembly, traceability checking, and labeling. Compress that timeline anywhere and the compression lands on remediation, which is the one phase you cannot skip without leaving open findings visible in your own report.

Decide the interface scope early and defend it in writing. The most common first-submission gap is a package that covers device firmware thoroughly and treats the mobile app, the cloud API, and the update mechanism as out of scope. Under the Feb 3, 2026 premarket guidance, the system boundary includes everything the device communicates with. If something genuinely is out of scope, write the justification into the scope statement rather than leaving the omission for a reviewer to notice.

Handle third-party and legacy components before they surprise you. An off-the-shelf module with an unmaintained upstream, a bootloader nobody has version information for, or a chipset stack you cannot inspect will each generate questions. Document what you know, what you cannot determine, and what compensating controls and monitoring you have in place. A documented limitation is a different conversation than a silent gap.

Use a Q-Sub if any of your scoping choices are genuinely debatable. A written answer from the agency costs you weeks. A deficiency letter costs you months.

If you are already inside six months, the highest-value move is booking penetration testing now and treating the threat model refresh as the input to that scope.

FDA Premarket Cybersecurity Service - the sequenced package built against your filing date, with remediation time preserved.
Premarket FDA Cybersecurity Submission Checklist - the item-by-item completeness standard to measure your package against.
FDA Cybersecurity Deficiency Response Timeline and Sequencing - the recovery path if a letter arrives anyway.
Submission Pathway Selector - work out whether the device fits 510(k), De Novo or PMA.